Results 151 to 160 of about 30,241 (215)

Feasibility and Safety Profile of Non‐anesthesiologist‐administered Propofol During Colorectal Endoscopic Submucosal Dissection: A Single‐center Study of 454 Procedures

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Objectives Studies of non‐anesthesiologist‐administered propofol (NAAP) during colorectal endoscopic submucosal dissection (ESD) are scarce, particularly in the elderly. We evaluated its feasibility across a broad age range and identified factors associated with sedation‐related adverse events.
Yumi Kishi   +16 more
wiley   +1 more source

Evaluation of Mutation Risk Using Patient‐Derived Organoids in Patients With Lynch Syndrome

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2585-2594, 15 November 2026.
ABSTRACT Lynch syndrome (LS) is a hereditary cancer predisposition syndrome caused by germline mutation of DNA mismatch repair (MMR) genes, most notably associated with colorectal cancer. Although LS patients face high risk of CRC, risk can vary even among those with the same pathogenic MMR germline mutations. We suggest a functional assay platform for
Youmi Shin   +10 more
wiley   +1 more source

Longitudinal Swallowing and Salivary Changes With CLR 131 and Re‐Irradiation in Recurrent Head and Neck Cancer

open access: yesHead &Neck, Volume 48, Issue 11, Page 3032-3042, November 2026.
ABSTRACT Background Patients with recurrent head and neck cancer (HNC) often present with severe, persistent dysphagia and xerostomia following prior chemoradiation. Although swallowing impairments and salivary dysfunction have been reported in this population, prior longitudinal studies have not examined changes in salivary composition or how these ...
Jenni Wu   +8 more
wiley   +1 more source

Protocol for the Therapy Personalisation Using Multiomic Analyses in Inflammatory Bowel Disease (THAMES‐IBD) Study

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
ABSTRACT Background Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the gut microbiome and ...
John P. Thomas   +14 more
wiley   +1 more source

Protocol: Early Intestinal Ultrasonography for Prediction of Response to Corticosteroids or Biologics in Outpatients With Moderate to Severe Ulcerative Colitis

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
A prospective study of 150 outpatients with moderate‐to‐severe UC initiating treatment. IUS is performed at baseline, day‐2, ‐7, ‐90 and week 52 alongside clinical, biochemical, endoscopic, patient‐reported and exploratory multiomics assessments. The primary endpoint evaluates whether early change in BWT predicts treatment escalation within 3 and 12 ...
Sabrina Josefsen   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy